| Today's Big NewsOct 21, 2022 |
|
Greater Philadelphia offers bioscience companies space to develop in close proximity to its world-class University City research center and global airport. From production to R&D, learn how the region can be your launchpad for growth and expansion. 
|
|
| By Nick Paul Taylor Ten months after revealing a phase 3 flop, Summit Therapeutics has shared data from the antibiotic trial and framed it as evidence of a potential need to change how anti-infectives are developed and assessed. |
|
|
|
By Annie Burky Advocate Aurora Health is notifying all 3 million of its patients that their health data may have been exposed through tracking technology. The health system, one of the Chicago area’s largest healthcare providers, explained in a statement on its website that through the use of internet tracking technologies certain interactions on the provider’s website were leaked. |
By Angus Liu GSK is banking on long-acting cabotegravir for growth in its HIV department. At least one team of analysts believes the company has the winning formula, and real-world evidence has started backing the case. |
By Andrea Park Roy Jakobs took over the role of CEO of Philips on Oct. 15, amid a tricky time for the devicemaker, which continues to grapple with the vast recall of many of its CPAP and BiPAP machines that began in the summer of 2021. |
By James Waldron Whisper it, but biotech SPACs appear to be back in fashion. The latest is cancer-focused Aum Biosciences, which is merging with blank check company Mountain Crest Acquisition to put its MNK and TRK inhibitors into phase 2 testing. |
By Fraiser Kansteiner Scynexis has laid out a strategy to “refocus its resources” on the clinical development of its antifungal ibrexafungerp in “hospital-based indications in which higher long-term returns are expected.” In turn, the company will license out the drug in its approved indication and terminate its entire commercial team. |
By Andrea Park Quest Diagnostics has seen its base business rebound in direct relation to dropping COVID-related earnings. |
By Robert King Nonprofit community Medicare Advantage plans made up one-third of plans that garnered five stars, an analysis from the Alliance of Community Health Plans. |
By Nick Paul Taylor With Halloween around the corner, the bogeyman of biotech—high placebo rate—has spooked investors in Immunic, sending its stock down 71% to $2.60 in premarket trading. The company blamed the response rate in the placebo arm for a disappointing look at interim, blinded data from its phase 1b psoriasis trial. |
By Conor Hale Known as conduction system pacing, the approach involves connecting the implant’s leads directly to the bundles of intertwined cells that help govern the repeated contractions of the cardiac muscle. |
By Zoey Becker Changes in exchange rates will likely have a heavy impact on third-quarter earnings, ODDO analysts said in a recent note. For certain European drugmakers such as Sanofi and GSK, the stronger dollar should help their financials, the team said. |
By Paige Minemyer In a filing with the Securities and Exchange Commission, CVS Health said that the Department of Justice sent the companies a second request for information on the merger on Oct. 19. |
By Gabrielle Masson In a move to become a “pure play” RNA company, Altamira Therapeutics is selling off 90% of its Zilentin subsidiary and its inner ear R&D work for the chance to make up to $55 million in biobucks. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now. 
|
|
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
